# Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

> **NCT07059091** · PHASE2 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 334 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)
- Allergies

## Interventions

- **DRUG:** Omalizumab (Xolair®)
- **DRUG:** Sodium Chloride (NaCl) 0.9 %

## Key facts

- **NCT ID:** NCT07059091
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-12
- **Primary completion:** 2031-01
- **Final completion:** 2031-05
- **Target enrollment:** 334 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07059091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07059091, "Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07059091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*